New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 22, 2013
14:09 EDTBX, LIFE, TMO, CG, DHRPE firms dropping out of bidding for Life Technologies, Bloomberg says
The odds are growing that if Life Technologies (LIFE) is sold it will be to either Danaher (DHR) or Thermo Fisher (TMO) as private equity firms drop out of the bidding, according to Bloomberg, citing people familiar with the process. KKR (KKR), which was part of a group of bidders, has withdrawn from the process, as has TPG, which was bidding along with Blackstone Group (BX), Carlyle Group (CG), and Temasek Holdings, the report said. Reference Link
News For LIFE;DHR;TMO;BX;CG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 13, 2015
07:33 EDTDHRDanaher to separate into two independent, publicly traded companies
07:31 EDTDHRPall Corp. to be acquired by Danaher for $13.8B including assumed debt
Subscribe for More Information
07:31 EDTDHRPall Corp agrees to be acquired by Danaher for $127.20 per share in cash
Subscribe for More Information
07:30 EDTDHRPall Corp agrees to be acquired by Danaher for $127.20 per share in cash
Subscribe for More Information
06:04 EDTBXBlackstone in discussions to buy Mega from Alon Group, Globes reports
Blackstone is in discussions to buy Mega, an Israeli supermarket retail chain, from Alon Group, Globes reports, citing sources. Blackstone has no current investments in Israel, the publication notes, adding that it is possible that Blackstone will partner with instead of buying Mega. Reference Link
05:48 EDTDHRStocks with implied volatility movement; DHR X
Subscribe for More Information
May 12, 2015
16:25 EDTTMO, DHROn The Fly: Top stock stories for Tuesday
Stocks began the session deep in negative territory as bond yields in Europe and the U.S. were moving higher. The market saw its lows shortly after the open and soon began to recapture some of its losses. By noon, the losses were cut in half and the Dow made it all the way back to positive ground by the afternoon. Unable to gather any upside momentum, the rally stalled and the averages limped into the close. ECONOMIC EVENTS: In the U.S., the National Federation of Independent Business' small business optimism rose 1.7 points to 96.9 in April, versus expectations for a 96.0 reading. The JOLTs report showed job openings fell 150K to 4.99M in March, versus expectations for 5.11M openings. The 10-year U.S. Treasury yield climbed at high as 2.37% earlier in the session, which was its highest intraday mark since last November, before easing back by midday. Outside of the U.S., bond yields surged on 10-year notes in Japan, Italy, Spain, Portugal, and Germany. COMPANY NEWS: Shares of AOL (AOL) advanced $7.93, or 18.62%, to $50.52 after Verizon (VZ) agreed to buy the company for $50 per share in a deal valued at $4.4B. Verizon's John Stratton, speaking at the Jefferies 2015 Global TMT Conference, said the AOL deal was primarily about ad technology and Re/code reported that "one scenario" the service has heard about is that Verizon plans to spin off some or all of the content operations it is acquiring by buying AOL, such as the Huffington Post. Yahoo (YHOO) also rose 24c, or 0.55%, to $43.84, as Cantor Fitzgerald analyst Youssef Squali said he now views it as the "last remaining large scale digital media company of its kind." MAJOR MOVERS: Among the notable gainers was Pall Corp. (PLL), which advanced $19.31, or 19.44%, to $118.62 after The Wall Street Journal reported that the company is near a possible sale and listed Danaher (DHR) and Thermo Fisher (TMO) as potential buyers. Also higher was Pain Therapeutics (PTIE), which gained 68c, or 35.05%, to $2.62 after announcing that a study of its lead drug candidate, that is specifically designed to discourage certain common methods of drug tampering and misuse, demonstrated with statistical significance that both intact and chewed Remoxy were less "liked" than immediate-release oxycodone on the two primary endpoints of Drug Liking and Drug High. Among the noteworthy losers was ITT Educational Services (ESI), which plunged $1.75, or 43.53%, to $2.27 after the SEC announced that it had charged the company, along with its CEO and CFO, with fraud. Also lower were shares of NewLink Genetics (NLNK), which dropped $15.59, or 29.9%, to $36.55 after stating that it would continue its flagship IMPRESS trial as planned despite disclosing the FDA did not endorse management's plan to change the statistical analysis plan as defined in the original protocol. INDEXES: The Dow fell 36.94, or 0.2%, to 18,068.23, the Nasdaq slid 17.38, or 0.35%, to 4,976.19, and the S&P 500 dropped 6.21, or 0.29%, to 2,099.12.
16:01 EDTDHROptions Update; May 12, 2015
Subscribe for More Information
14:04 EDTDHR, TMOPall Corp. a better strategic fit for Thermo Fisher than Danaher, says Mizuho
Subscribe for More Information
12:34 EDTDHR, TMOOn The Fly: Top stock stories at midday
Subscribe for More Information
10:54 EDTBXBlackstone acquires three shopping centers in Spain, Portugal
Subscribe for More Information
10:45 EDTDHR, TMOAnalyst says Pall deal may spark more life sciences M&A
Subscribe for More Information
09:51 EDTDHRPall Corp. could be precursor to more Life Science deals, says Janney Capital
After The Wall Street Journal said Pall Corp. (PLL) is nearing a possible sale, naming Thermo Fisher (THO) and Danaher (DHR) as potential suitors, Janney Capital said it thinks dealmaking in the Life Sciences space won't stop with Pall, listing Repligen (RGEN), Bio-Techne (TECH) and VWR (VWR) as others in the industry that could see strategic bids emerge. The firm added that it expects that GE (GE), 3M (MMM), and private equity firms would also be involved in bidding in deals in the space.
09:47 EDTDHR, TMOPall Corp. bids due later this week, CNBC's Faber reports
David Faber on CNBC reported that bids for Pall Corp. (PLL) from Danaher (DHR) and Thermo Fisher (TMO) are due later this week. The auction is being led by Goldman Sachs (GS), Faber adds. He notes Danaher is likely going to offer an all-cash bid whereas Thermo Fisher will use up to $2B of equity. Faber said an offer price of $120 per share for Pall is likely the top of the range. The Wall Street Journal reported last night some of these details.
07:46 EDTDHR, TMODanaher has upper hand to acquire Pall, says Jefferies
After the Wall Street Journal reported that Pall Corp. (PLL) is near a possible sale and listed Danaher (DHR) and Thermo Fisher (TMO) as potential buyers, Jefferies says it believes Danaher has the upper hand in getting the deal done given its greater relative balance sheet capacity. The firm views both companies as logical buyers for Pall and notes a takeout bid of around $13B implies a share price of $120. The firm has a Buy rating on Pall.
07:31 EDTTMOThermo Fisher acquisition of Pall Corp. could create 'powerhouse,' says UBS
UBS noted Thermo Fisher (TMO) was mentioned in a media report as a possible suitor for Pall Corp. (PLL) and feels if the two combine it could create a bio-production "powerhouse." The firm sees a potential deal as accretive and creating unparalleled scale. UBS also said that, based on current valuation, the potential for a deal is barely being priced into Thermo Fisher shares. UBS reiterated its Buy rating and $160 price target on Thermo Fisher shares.
06:30 EDTDHR, TMOPall volatility flat, Danaher, Thermo Fisher to submit final bids, WSJ reports
Subscribe for More Information
May 11, 2015
19:22 EDTTMO, DHRDanaher, Thermo Fisher to submit final bids for Pall, WSJ says
Danaher (DHR) and Thermo Fisher (TMO) are competing to acquire Pall (PLL), with final bids due later this week, reports The Wall Street Journal, citing people familiar with the matter. A deal could be valued at $13B or more, notes the Journal. Reference Link
09:02 EDTCGComcast names Michael Cavanagh as CFO
Subscribe for More Information
May 10, 2015
16:46 EDTBXBlackstone says SEC requests information on fee practices, vendor discounts
In a regulatory filing Friday, Blackstone stated, "The SEC has publicly indicated that it is focused on private equity practices regarding fees and other conflicts of interest including the... practice of receiving fees from portfolio companies in connection with termination of monitoring agreements upon the initial public offering or disposition of such companies. The SEC reviewed our monitoring fee practices in 2011-2012 in their regular exam process... In June 2014, we voluntarily modified our monitoring fee practices... including eliminating any such payments beyond the year of sale for full dispositions and limiting payments following IPOs. Recently, the SEC has informally requested additional information about our historical monitoring fee termination practices. The SEC also has asked for additional information about certain pre-2011 practices relating to the application of disparate vendor discounts to Blackstone and to our funds that were changed in 2011 and had also been previously reviewed by the SEC in 2012. We are in discussions with the SEC regarding a potential resolution of these matters."
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use